

AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Use of a FADS2 interacting molecule for the preparation of a~~ A pharmaceutical composition for the treatment of neurogenerative diseases comprising a FADS2 interacting molecule.
2. (Currently amended) The ~~use~~ pharmaceutical composition of claim 1, wherein the FADS2-interacting molecule is a FADS2 inhibitor.
3. (Currently amended) The ~~use~~ pharmaceutical composition of claim 2, wherein the FADS2 inhibitor is selected from the group consisting of antibodies, antisense oligonucleotides, siRNA, low molecular weight molecules (LMWs), binding peptides, aptamers, and ribozymes.
4. (Currently amended) The ~~use of any of claims 1 to 3~~ pharmaceutical composition of claim 1, wherein the FADS2 is part of a protein complex comprising at least ~~on~~ one further protein selected from the proteins as listed in table 1, third column.
5. (Currently amended) The ~~use of any of claims 1 to 4~~ pharmaceutical composition of claim 1, wherein the FADS2 interacting molecule ~~or inhibitor~~ modulates the activity of gamma secretase and/or beta secretase.
6. (Currently amended) The ~~use of any of claims 1 to 5~~ pharmaceutical composition of claim 1, wherein the neurodegenerative disease is Alzheimer's disease.
7. (Currently amended) A method for identifying a gamma secretase and/or a beta secretase modulator[[,]] comprising the following steps:
 - a a). identifying of a FADS2-interacting molecule by determining whether a given test compound is a FADS2-interacting molecule, and
 - ~~b~~ b). determining whether the FADS2-interacting molecule of step a) is capable of modulating gamma secretase and/or beta secretase activity.
8. (Original) The method of claim 7, wherein in step a) the test compound is brought into contact with FADS2 and the interaction of FADS2 with the test compound is determined.

9. (Original) The method of claim 8, wherein the interaction of the test compound with FADS2 results in an inhibition of FADS2 activity.

10. (Currently amended) The method of ~~any of claims 7 to 9~~ claim 7, wherein in step b) the ability of the gamma secretase and/or the beta secretase to cleave APP is measured.

11. (Currently amended) A method for preparing a pharmaceutical composition for the treatment of neurodegenerative diseases[[,]] comprising the following steps:

a a). identifying a gamma secretase and/or beta secretase modulator according to ~~claims 7 to 11~~ claim 7, and

b b). formulating the gamma secretase and/or beta secretase modulator to a pharmaceutical composition.

12. (Original) A protein complex comprising

a) FADS2 and

b) either one or more proteins of the Nicastrin (a) complex, of the Nicastrin (b) complex, of the Nicastrin (c) complex, of the BACE1-complex (a), of the BACE1-complex (b), of the Psen2-complex or of the PTK7 complex.

13. (Currently amended) The complex of claim ~~5~~ 12, wherein the one ore more proteins of the Nicastrin (a) complex are selected from the group consisting of

(i)"18 kDa microsomal signal peptidase subunit" (SEQ ID No: 53)

(ii) "25 kDa microsomal signal peptidase subunit" (SEQ ID No: 119)

(iii) "ATP-binding cassette, sub-family A, member 3" (SEQ ID No: 103),

(iv)"Aph-1a" (SEQ ID No: 1),

(v)"BACE1" (SEQ ID No : 68),

(vi)"BSCv protein" (SEQ ID No: 70),

- (vii) "CGI-13" (SEQ ID No: 72)
- (viii)"Casein kinase II beta chain" (SEQ ID No: 74),
- (ix)"Cathepsin B" (SEQ ID No: 75),
- (x)"ENSG00000144840" (SEQ ID No: 79)
- (xi) "FLJ13977" (SEQ ID No: 81),
- (xii) "FLJ20342" (SEQ ID No: 56),
- (xiii)"FLJ20481" (SEQ ID No: 82),
- (xiv)"FLJ22390" (SEQ ID No: 84),
- (xv)"Hypothetical protein tyrosine phosphatase ensgO0000149185" (SEQ ID No : 86),
- (xvi)"ICAM-2" (SEQ ID No: 87)
- (xvii)"KIAA1181" (SEQ ID No : 88),
- (xiii)"KIAA1533" (SEQ ID No: 89),
- (xix)"Mesenchymal stem cell protein DSCD75" (SEQ ID No: 91)
- (xx)"NICE-3" (SEQ ID No: 58), (xxi)"Neurotypsin" (SEQ ID No: 92),
- (xxii)"Nicastrin" (SEQ ID No: 9),
- (xxiii)"PP1, regulatory subunit 15B" (SEQ ID No: 93)
- (xxiv)"Pen-2" (SEQ ID No: 10) (xxv)"Presenilin-1" (SEQ ID No: 14),
- (xxvi)"Presenilin-2" (SEQ ID No : 66),
- (xxvii)"Protein amplified in osteosarcoma (OS-9) " (SEQ ID No: 94)
- (xxviii) "Protein similar to stromal cell-derived factor 2" (SEQ ID No: 95)
- (xxix) "Protocadherin beta 8" (SEQ ID No: 96) (xxx)"REP8 protein" (SEQ ID No: 97)

(xxxi) "RING finger. protein 5" (SEQ ID No: 98)

(xxxii) "Retinal short-chain dehydrogenase/reductase retSDR2" (SEQ ID No: 99)

(xxxiii) "Stromal cell-derived factor 2-like 1" (SEQ ID No: 100)

(xxxiv) "Thioredoxin domain-containing protein" (SEQ ID No: 101), and

(xxxv) "Voltage-dependent anion channel 1" (SEQ ID No: 102),

and wherein the one or more proteins of the Nicastrin (b) complex are selected from the group consisting of

(i) "18 kDa microsomal signal peptidase subunit" (SEQ ID No: 53)

(ii) "25 kDa microsomal signal peptidase subunit" (SEQ ID No: 119)

(iii) "ATP-binding cassette, sub-family A, member 3" (SEQ ID No: 103)

(iv) "Aph-1a" (SEQ ID No: 1)

(v) "BACE1" (SEQ ID No: 38)

(vi) "BSCv protein (FRAGMENT)" (SEQ ID No: 70)

(vii) "CAMK4" (SEQ ID No: 104)

(viii) "CGI-13" (SEQ ID No: 72)

(ix) "Casein kinase II beta chain" (SEQ ID No: 74)

(x) "Cathepsin B" (SEQ ID No: 75)

(xi) "DCTN1" (SEQ ID No: 106)

(xii) "ENSG00000144840" (SEQ ID No: 79)

(xiii) "FACL3" (SEQ ID No: 108)

(xiv) "FACL4" (SEQ ID No: 109)

- (xv)"FLJ13977" (SEQ ID No: 81)
- (xvi) "FLJ20342" (SEQ ID No: 56)
- (xvii)"FLJ20481" (SEQ ID No: 82)
- (xiii) "FLJ22390" (SEQ ID No: 84)
- (xix) "ICAM-2" (SEQ ID No: 87)
- (xx)"KIAA0095" (SEQ ID No: 110)
- (xxi) "KIAA0922" (SEQ ID No: 111)
- (xxii)"KIAA1181 (FRAGMENT) " (SEQ ID No : 88)
- (xxiii) "KIAA1533 (FRAGMENT) " (SEQ ID No: 89)
- (xxiv)"Mesenchymal stem cell protein DSCD75" (SEQ ID No: 91)
- (xxv) "NICE-3" (SEQ ID No: 58)
- (xxvi)"Neurotrypsin" (SEQ ID No: 92)
- (xxvii) "Nicastrin" (SEQ ID No: 9)
- (xxiii) "PAS domain containing serine/threonine kinase" (SEQ ID No: 112)
- (xxix)"PP1, regulatory subunit 15B" (SEQ ID No: 93)
- (xxx) "Pen-2" (SEQ ID No: 10)
- (xxxi)"Presenilin-1" (SEQ ID No: 14)
- (xxxii) "Presenilin-2" (SEQ ID No : 66)
- (xxxiii) "Protein amplified in osteosarcoma (OS-9) " (SEQ ID No: 94)
- (xxxiv) "Protein similar to stromal cell-derived factor 2" (SEQ ID No: 95)
- (xxxv)"Protocadherin beta 8" (SEQ ID No: 96)

(xxxvi) "REP8 protein" (SEQ ID No: 97)

(xxxvii) "RING finger protein 5" (SEQ ID No: 98)

(xxxiii) "Retinal short-chain dehydrogenase/reductase retSDR2" (SEQ ID No: 99)

(xxxix) "Stromal cell-derived factor 2-like 1" (SEQ ID No: 100)

(xl) "Thioredoxin domain-containing protein" (SEQ ID No: 101)

(xli) "homolog of yeast golgi membrane protein yiflp (yiplp-interacting factor)" (SEQ ID No: 113), and

(xlii) "tyrosine phosphatase ensg00000149185" (SEQ ID No : 86),

and wherein the one or more proteins of the Nicastrin (c) complex are selected from the group consisting of

(i) "APP-C99" (SEQ ID No: 120)

(ii) "Nicastrin" (SEQ ID No: 9)

(iii) "Psen1" (SEQ ID No : 3)

(iv) "aph-1a" (SEQ ID No : 1)

(v) "APP" (SEQ ID No: 23)

(vi) "CtnnA1" (SEQ ID No: 47)

(vii) "CtnnA2" (SEQ ID No: 48)

(viii) "CtnnB1" (SEQ ID No: 46)

(ix) "CtnnD1" (SEQ ID No: 49)

(x) "JUP" (SEQ ID No: 2)

(xi) "NCadh" (SEQ ID No: 50)

- (xii)"ACAT1" (SEQ ID No: 4)
- (xiii) "CGI-13" (SEQ ID No: 72)
- (xiv) "CK2B" (SEQ ID No : 59)
- (xv)"CLGN" (SEQ ID No: 54)
- (xvi) "ECSIT" (SEQ ID No: 55)
- (xvii) "FACL3" (SEQ ID No: 11)
- (xiii) "FLJ20481" (SEQ ID No: 82)
- (xix) "ITM2C" (SEQ ID No: 13)
- (xx)"ITPR1" (SEQ ID No: 16)
- (xxi)"KIAA0363" (SEQ ID No: 105)
- (xxii)"MDR1" (SEQ ID No: 18)
- (xxiii) "Neurotrypsin" (SEQ ID No: 19)
- (xxiv) "PTP LOC114971" (SEQ ID No: 60)
- (xxv) "RetSDR2" (SEQ ID No: 21)
- (xxvi)"SFXN1" (SEQ ID No: 24)
- (xxvii)"SPC18" (SEQ ID No: 26)
- (xxiii) "SPC22" (SEQ ID No: 27)
- (xxix) "SPC25" (SEQ ID No: 28)
- (xxx) "SPTLC2" (SEQ ID No : 117)
- (xxxi) "stearoyl-CoA desaturase" (SEQ ID No: 29)
- (xxxii) "STT3" (SEQ ID No: 61)

(xxxiii) "TMP21" (SEQ IDNo : 30)

(xxxiv) "UGCGL1" (SEQ ID No: 45)

(xxxv) "visinin-like 1" (SEQ ID No: 37)

(xxxvi)"Wolframin" (SEQ ID No: 67), and

(xxxvii)"YME1L1" (SEQ ID No : 32)

and wherein the one or more proteins of BACE1 (a) complex are selected from the group consisting of

(i) "CGI-13" (SEQ ID No: 72)

(ii) "Cadherin EGF LAG seven-pass G-type receptor 2" (SEQ ID No: 35)

(iii) "Calsyntenin 1" (SEQ ID No: 36)

(iv)"Delta-like homolog" (SEQ ID No: 118)

(v)"FLJ30668" (SEQ ID No: 69)

(vi)"PLJ39249" (SEQ ID No: 71)

(vii)"ITCH" (SEQ ID No: 73)

(viii)"KIAA1250" (SEQ ID No: 107)

(ix)"Nicastrin" (SEQ ID No: 9)

(x)"Nogo-A" (SEQ ID No: 77)

(xi)"PDGFRB" (SEQ ID No: 78)

(xii) "PTK7" (SEQ ID No: 80)

(xii)"SERPINA1" (SEQ ID No: 83)

(xiv)"SIM TO Y71H10A. 2. P" (SEQ ID No: 85)

(xv) "STX10" (SEQ ID No: 65)

(xvi) "Sortilin-related receptor" (SEQ ID No: 52)

(xvii) "Thioredoxin domain-containing protein" (SEQ ID No: 101)

(xviii) "integral membrane transporter protein" (SEQ ID No: 114)

(xix) "kinectin 1 (kinesin receptor) " (SEQ ID No: 90), and

(xx)"BACE1" (SEQ ID No: 38),

and wherein the one or more proteins of the BACE1 (b) complex are selected from the group consisting of

(i)"APP" (SEQ ID No : 23)

(ii) "Nicastrin" (SEQ ID No: 9)

(iii)"ACAT1"(SEQID No: 4)

(iv)"APLP2" (SEQ ID No: 22)

(v)"BRI" (SEQ ID No: 5)

(vi)"calsyntenin 1" (SEQ ID No : 6)

(vii)"CELSR2" (SEQ ID No: 39)

(viii) "CGI-13" (SEQ ID No: 72)

(ix)"DLK1" (SEQ ID No: 7)

(x)"DSCD75" (SEQ ID No : 8)

(ii) "FADS2" (SEQ ID No: 40)

(xii)"GPR49" (SEQ ID No: 115)

(xiii)"ITM2C" (SEQ ID No: 13)

- (xiv) "KiDins220" (SEQ ID No: 17)
- (xv) "LAPTM4B" (SEQ ID No: 33)
- (xvi) "Neurotrypsin" (SEQ ID No: 19)
- (xvii) "NogoA" (SEQ ID No: 41)
- (xviii) "OS-9" (SEQ ID No: 42)
- (xix) "PDGFRB" (SEQ ID No: 43)
- (xx) "PTK7" (SEQ ID No: 44)
- (xxi) "RetSDR2" (SEQ ID No: 21)
- (xxii) "SIOOalpha" (SEQ ID No: 34)
- (xxiii) "SORL1" (SEQ ID No: 25)
- (xxiv) "stearoyl-CoA desaturase" (SEQ ID No: 29)
- (xxv) "TMP21" (SEQ ID No: 30)
- (xxvi) "UGCGL1" (SEQ ID No: 45), and
- (xxvii) "BACE1" (SEQ ID No: 38)

and wherein the one or more proteins of the Psen2-complex are selected from the group consisting of

- (i) "aph-1a" (SEQ ID No : 1)
- (ii) "Nicastrin" (SEQ ID No: 9)
- (iii) "CGI-13" (SEQ ID No: 72)
- (iv) "DSCD75" (SEQ ID No : 8)
- (v) "ECSIT" (SEQ ID No: 55)

- (vi) "FACL3" (SEQ ID No: 11)
- (vii) "FADS2" (SEQ ID No: 40)
- (viii) "FLJ10579" (SEQ ID No: 12)
- (ix) "FLJ20481" (SEQ ID No: 82)
- (x) "ITPR1" (SEQ ID No: 16)
- (xi) "KIAA0090" (SEQ ID No: 57)
- (xii) "MDR1" (SEQ ID No: 18)
- (xiii) "NicAChRa3" (SEQ ID No: 62)
- (xiv) "PLD3" (SEQ ID No: 20)
- (xv) "SFXN1" (SEQ ID No: 24)
- (xvi) "SLC4A2" (SEQ ID No: 63)
- (xvii) "SORT1" (SEQ ID No: 15)
- (xviii) "SPC18" (SEQ ID No: 26)
- (xix) "SPC22" (SEQ ID No: 27)
- (xx) "SPC25" (SEQ ID No: 28)
- (xxi) "SPTLC2" (SEQ ID No: 117)
- (xxii) "stearoyl-CoA desaturase" (SEQ ID No: 29)
- (xxiii) "STT3" (SEQ ID No: 61)
- (xxiv) "TMP21" (SEQ ID No: 30)
- (xxv) "VLCAD" (SEQ ID No: 31)
- (xxvi) "Wolframin" (SEQ ID No: 67)

(xxvii) "YME1L1" (SEQ ID No: 32), and

(xxvii) "Psen2" (SEQ ID No: 121)

and wherein the at least one protein of PTK7 complex is selected from the group consisting of[.]

(i) "APP" (SEQ ID No: 23)

(ii) "BRI" (SEQ ID No: 5)

(iii) "CELSR2" (SEQ ID No: 39)

(iv) "DLK1" (SEQ ID No : 7)

(v) "FADS2" (SEQ ID No: 40)

(vi) "HIFPH3/EGLN3" (SEQ ID No: 64)

(vii) "ITM2C" (SEQ ID No: 13)

(viii) "Nap1-like" (SEQ ID No: 116)

(ix) "Reelin" (SEQ ID No: 51), and

(x) "PTK7" (SEQ ID No: 44),

14. (Currently amended) The complex of ~~any of claims 12 or 13~~ claim 12, wherein one or more of the proteins are present in the form a fusion protein comprising said protein fused to an amino acid sequence different from that of the protein.

15. (Original) The complex of claim 14, wherein said amino acid sequence is an affinity tag or label.

16. (Currently amended) A process for preparing and optionally analyzing a the complex of ~~any of claims 12 to 15~~ claim 12 or of one or more components thereof comprising the following steps:

a). Expressing a protein of the complex, preferably a tagged protein, in a target cell,

b). isolating the protein complex which is attached to the protein, preferably a tagged protein, and

c). optionally disassociating the protein complex and isolating the individual complex members.

17. (Original) The process according to claim 16, wherein the tagged protein comprises two different tags which allow two separate affinity purification steps.

18. (Currently amended) The process according to ~~any of claims 16 or 17~~ claim 17, wherein the two tags are separated by a cleavage site for a protease.

19. (Currently amended) ~~Nucleic~~ A nucleic acid construct containing one or more nucleic acids encoding proteins of a the complex according to ~~any of claims 12 to 15~~ claim 12.

20. (Currently amended) ~~Host~~ A host cell[[,]] containing a the nucleic acid construct according to claim 19.

21. (Currently amended) A kit comprising, in one container, the complex of ~~any of claims 12 to 15~~ claim 12, optionally together with an antibody against the complex and/or further components such as reagents and working instructions.

22. (Currently amended) The kit according to claim ~~13~~ 21 for processing a substrate of a the complex of ~~any one of claims 12 to 15~~ claim 12.

23. (Currently amended) The kit according to ~~any of claims 21 or 22~~ claim 21 for the diagnosis or prognosis of a disease or a disease risk, preferentially for a disease or disorder such as neurodegenerative disease such as Alzheimer's disease and related neurodegenerative disorders.

24. (Currently amended) ~~Array~~ An array in which at least a the complex according to ~~any of claims 12 to 15~~ claim 12 is attached to a solid carrier.

25. (Currently amended) A process for processing a substrate of a the complex of ~~any one of claims 12 to 15~~ claim 12 comprising the step of bringing into contact a the complex ~~to any of claims 12 to 15~~ of claim 12 with said substrate[[,]] such that said substrate is processed.

26. (Currently amended) A pharmaceutical composition comprising the protein complex of ~~any of claims 12 to 15~~ claim 12.

27. (Currently amended) The pharmaceutical composition according to claim 26 for the treatment of neurodegenerative disease such as Alzheimer's disease and related neurodegenerative disorders.

28. (Currently amended) A method for screening for a molecule that binds to the complex of ~~any one of claims 12 to 15~~, claim 12 comprising the following steps:

(a) exposing said complex, or a cell or organism containing said complex, to one or more candidate molecules; and

(b) determining whether said candidate molecule is bound to the complex.

29. (Currently amended) A method for screening for a molecule that modulates directly or indirectly the function, activity, composition or formation of the complex of ~~any one of claims 1 to 7~~ claim 12 comprising the steps of:

(a) exposing said complex, or a cell or organism containing said complex to one or more candidate molecules; and

(b) determining the amount of, activity of, protein components of, and/or intracellular localization of, said complex.

30. (Original) The method of claim 29, further comprising the step of determining whether said candidate molecule modulates gamma secretase and/or beta secretase activity.

31. (Currently amended) The method of ~~any of claims 29 or 30~~ claim 29, wherein the amount of said complex is determined.

32. (Currently amended) The method of ~~any of claims 29 or 30~~ claim 29, wherein the activity of said complex is determined.

33. (Currently amended) The method of claim ~~32~~ 29, wherein said determining step comprises isolating from the cell or organism said complex to produce said isolated complex and contacting said isolated complex in the presence or absence of a candidate molecule with a substrate of said complex and determining whether said substrate is processed in the absence of the candidate molecule and whether the processing of said substrate is modified in the presence of said candidate molecule.

34. (Original) The method of claim 33, wherein the substrate is APP and the cleavage of APP is analyzed.

35. (Currently amended) The method of ~~any of claims 29 or 30~~ claim 29, wherein the amount of the individual protein components of said complex are determined.

36. (Canceled)

37. (Currently amended) The method of ~~any of claims 29 to 36~~ claim 29, wherein said method is a method of screening for a drug for treatment or prevention of neurodegenerative disease such as Alzheimer's disease.

38-40. (Canceled)

41. (Currently amended) A method for the production of a pharmaceutical composition comprising carrying out the method of ~~any of claims 28 to 37~~ claim 28 and further comprising mixing the identified molecule with a pharmaceutically acceptable carrier.

42. (Currently amended) A method for diagnosing or screening for the presence of a disease or disorder or a predisposition for developing a disease or disorder in a subject, which disease or disorder is characterized by an aberrant amount of, component disposition of, or intracellular localization of the complex of ~~any one of claims 12 to 15~~ claim 12, comprising determining the amount of, activity of, protein components of, and/or intracellular localization of, said complex.

43. (Original) The method of claim 42, wherein the activity of gamma secretase and/or beta secretase is determined.
44. (Currently amended) The method of ~~any of claims 42 or 43~~ claim 42, wherein the amount of said complex is determined.
45. (Currently amended) The method of ~~any claim 42 or 43~~ claim 42, wherein the activity of said complex is determined.
46. (Currently amended) The method of claim ~~45~~ 42, wherein said determining step comprises isolating from the cell or organism said complex to produce said isolated complex and contacting said isolated complex in the presence or absence of a candidate molecule with a substrate of said complex and determining whether said substrate is processed in the absence of the candidate molecule and whether the processing of said substrate is modified in the presence of said candidate molecule.
47. (Currently amended) The method of ~~any of claims 42 or 43~~ claim 42, wherein the amount of the individual protein components of said complex are determined.
48. (Canceled)
49. (Currently amended) The ~~complex of any one of claims 12 to 15, for use in a method of diagnosing a disease or disorder, preferentially of a~~ method of claim 42, wherein the disease or disorder ~~such as is~~ is a neurodegenerative disease such as Alzheimer's disease and related neurodegenerative disorders.
50. (Currently amended) A method for treating or preventing a disease or disorder characterized by an aberrant amount of, activity of, component composition of or intracellular localization of ~~[[,]] the complex of any one of claims 12 to 15~~ claim 12, comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more molecules that modulate the amount of, activity or, or protein components of, said complex.

51. (Currently amended) The method according to claim 50, wherein the ~~modulating~~
modulating molecule is a FADS2 interacting molecule, preferably a FADS2-inhibitor.

52. (Canceled)

53. (Currently amended) The method according to ~~any of claims 50 to 52~~ claim 50, wherein
said disease or disorder involves decreased levels of the amount or activity of said complex.

54. (Currently amended) The method according to ~~any of claims 50 to 53~~ claim 50, wherein
said disease or disorder involves increased levels of the amount or activity of said complex.

55. (Currently amended) The complex of ~~any of claims 12 to 15 as~~ claim 12, where in the
complex is a target for an active agent of a pharmaceutical, preferably a drug target in the
treatment or prevention of a disease or disorder, preferentially of a disease or disorder such as
neurodegenerative disease such as Alzheimer's disease and related neurodegenerative disorders.

56. (Canceled)

57. (New) A method for screening for a molecule that modulates directly or indirectly the
function, activity, composition or formation of a protein complex comprising FADS2 and either
one or more proteins of the Nicastrin (a) complex, of the Nicastrin (b) complex, of the Nicastrin
(c) complex, of the BACE1-complex (a), of the BACE1-complex (b), of the Psen2-complex or of
the PTK7 complex, wherein the method comprises the steps of:

(a) exposing said protein complex, or a cell or organism containing said protein complex to one
or more candidate molecules; and

(b) determining the amount of, activity of, protein components of, and/or intracellular
localization of said protein complex,

wherein said determining step comprises determining whether any of the proteins of the
respective complex as defined in claim 13 is present in the complex.

58. (New) A medicament for the treatment or prevention of a neurodegenerative disease such as Alzheimer's disease comprising a molecule that modulates the amount of, activity of, or the protein components of the complex of claim 12.
59. (New) The medicament according to claim 58, wherein the modulating molecule is a FADS2 interacting molecule, preferably a FADS2 inhibitor.
60. (New) The medicament according to claim 59, wherein the FADS2 inhibitor is selected from the group consisting of antibodies, antisense oligonucleotides, siRNA, low molecular weight molecules (LMWs), binding peptides, aptamers, and ribozymes.
61. (New) The medicament according to claim 59, wherein the FADS2 is part of a protein complex comprising at least on one further protein selected from the proteins as listed in table 1, third column.
62. (New) The medicament according to claim 59, wherein the FADS2 interacting molecule or inhibitor modulates the activity of gamma secretase and/or beta secretase.
63. (New) A method for the production of a pharmaceutical composition comprising carrying out the method of claim 29 and further comprising mixing the identified molecule with a pharmaceutically acceptable carrier.
64. (New) A method for diagnosing or screening for the presence of a disease or disorder or a predisposition for developing a disease or disorder in a subject, which disease or disorder is characterized by an aberrant amount of, component disposition of, or intracellular localization of a protein complex comprising FADS2 and either one or more proteins of the Nicastrin (a) complex, of the Nicastrin (b) complex, of the Nicastrin (c) complex, of the BACE1-complex (a), of the BACE1-complex (b), of the Psen2-complex or of the PTK7 complex comprising determining the amount of, activity of, protein components of, and/or intracellular localization of said protein complex, wherein said determining step comprises determining whether any of the proteins according to claim 13 is present in said protein complex.

65. (New) The method according to claim 51, wherein the FADS2 inhibitor is selected from the group consisting of antibodies, antisense oligonucleotides, siRNA, low molecular weight molecules (LMWs), binding peptides, aptamers, and ribozymes.
66. (New) The method according to claim 51, wherein the FADS2 is part of a protein complex comprising at least on one further protein selected from the proteins as listed in table 1, third column.
67. (New) The method according to claim 51, wherein the FADS2 interacting molecule or inhibitor modulates the activity of gamma secretase and/or beta secretase.
68. (New) The method according to claim 50, wherein the disease or disorder is a neurodegenerative disease such as Alzheimer's disease.